Role of chemotherapy in breast cancer

被引:12
作者
Hussain, Syed A. [1 ]
Palmer, Daniel H.
Stevens, Andrea
Spooner, David
Poole, Christopher J.
Rea, Daniel W.
机构
[1] Univ Birmingham, Birmingham, W Midlands, England
[2] Univ Hosp Birmingham, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England
关键词
advanced breast cancer; anthracyclines; breast cancer; gemcitabine; prognostic markers; sequential or concurrent radiotherapy; targeted therapies; taxanes;
D O I
10.1586/14737140.5.6.1095
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer represents a major health problem, with more than a million new cases and 370,000 deaths worldwide yearly. Options and understanding of how to use cytotoxic chemotherapy in both advanced and early stage breast cancer have made substantial progress in the past 10 years, with numerous landmark studies identifying clear survival benefits for newer approaches. Despite this research, the optimal approach for any individual patient cannot be determined from a literature review or decision-making algorithm alone. Treatment choices are still predominantly based on practice determined by individual or collective experience and the historic development of treatment within a locality. In many situations treatment decisions cannot be divorced from economic considerations. Blanket application of international, national or local guidelines is usually impractical or inappropriate and careful consideration of the detailed circumstances of each patient is required to make optimal use of available options. Recent research has allowed us to refine breast cancers further into prognostic groups based on a gene expression profile. Clinical trials to prove the value of this approach are currently being designed. This review discusses the evidence for various chemotherapy regimens in the adjuvant and metastatic settings, and examines the current evidence for the timing of radiotherapy in the adjuvant setting.
引用
收藏
页码:1095 / 1110
页数:16
相关论文
共 89 条
[1]  
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]   Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors:: 5-year follow-up results of French adjuvant study group 05 randomized trial [J].
Adenis, A ;
Bonneterre, J ;
Bonneterre, ME ;
Pion, JM ;
Vanlemmens, L ;
Gladieff, L ;
de Lafontan, B ;
Martel, P ;
Mihura, J ;
Roché, H ;
Gédouin, D ;
Kerbrat, P ;
Lesimple, T ;
Brémond, A ;
Devaux, Y ;
Delecroix, V ;
Fumoleau, P ;
Maugard-Louboutin, C ;
Namer, M ;
Goudier, MJ ;
Morice, F ;
Montcuquet, P ;
Schraub, S ;
Coudert, B ;
Fargeot, P ;
de Gislain, C ;
Mayer, F ;
Bastit, P ;
Chevallier, B ;
Grandgirard, A ;
Monnier, A ;
Sun, X ;
Clavère, P ;
Ollivier, JP ;
Rhein, B ;
Roullet, B ;
Datchary, J ;
Audhuy, B ;
Barats, JC ;
Kohser, F ;
Dides, S ;
Ramos, R ;
Cattan, A ;
Eymard, JC ;
Pourny, C ;
Weber, B ;
de Laroche, G ;
Pichon, A ;
Seffert, P ;
Hayat, M .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) :602-611
[3]  
ALBAIN K, 2004, P AM SOC CLIN ONCOL, V22
[4]  
[Anonymous], J CLIN ONCOL
[5]   The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27 [J].
Bear, HD ;
Anderson, S ;
Brown, A ;
Smith, R ;
Mamounas, EP ;
Fisher, B ;
Margolese, R ;
Theoret, H ;
Soran, A ;
Wickerham, DL ;
Wolmark, N .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4165-4174
[6]   Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-rise breast cancer [J].
Bellon, JR ;
Lindsley, KL ;
Ellis, GK ;
Gralow, JR ;
Livingston, RB ;
Seymour, MMA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (02) :393-397
[7]   Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: Updated results of a prospective randomized trial [J].
Bellon, JR ;
Come, SE ;
Gelman, RS ;
Henderson, IC ;
Shulman, LN ;
Silver, BJ ;
Harris, JR ;
Recht, A .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1934-1940
[8]   Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial [J].
Biganzoli, L ;
Cufer, T ;
Bruning, P ;
Coleman, R ;
Duchateau, L ;
Calvert, AH ;
Gamucci, T ;
Twelves, C ;
Fargeot, P ;
Epelbaum, R ;
Lohrisch, C ;
Piccart, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (14) :3114-3121
[9]   Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer [J].
Bishop, JF ;
Dewar, J ;
Toner, GC ;
Smith, J ;
Tattersall, MHN ;
Olver, IN ;
Ackland, S ;
Kennedy, I ;
Goldstein, D ;
Gurney, H ;
Walpole, E ;
Levi, J ;
Stephenson, J ;
Canetta, R .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2355-2364
[10]   Gemcitabine as first-line therapy in patients with metastatic breast cancer: A phase II trial [J].
Blackstein, M ;
Vogel, CL ;
Ambinder, R ;
Cowan, J ;
Iglesias, J ;
Melemed, A .
ONCOLOGY, 2002, 62 (01) :2-8